Trial Profile
Evaluate the effect of vemurafenib on BRAF V600E mutant papillary craniopharyngioma
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2017
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Craniopharyngioma
- Focus Therapeutic Use
- 30 Nov 2017 New trial record